Breaking Advances
Cancer Res April 1 2014 74 (7) 1883-1884;
Table of Contents
Breaking Advances
Reviews
- ReviewsNaoko Ohtani, Shin Yoshimoto and Eiji HaraCancer Res April 1 2014 74 (7) 1885-1889; DOI:10.1158/0008-5472.CAN-13-3501
- Reviews | AuthorChoiceGianluigi Giannelli, Erica Villa and Michael LahnCancer Res April 1 2014 74 (7) 1890-1894; DOI:10.1158/0008-5472.CAN-14-0243
Priority Report
- Priority ReportDaniel P. Kane and Polina V. ShcherbakovaCancer Res April 1 2014 74 (7) 1895-1901; DOI:10.1158/0008-5472.CAN-13-2892
This study describes the functional consequences of the most frequent DNA polymerase variant linked to colorectal and endometrial cancer, challenging the recently forwarded idea that hypermutated human cancers must result from loss of exonucleolytic proofreading.
Integrated Systems and Technologies
- Integrated Systems and Technologies | AuthorChoiceEletheria Panagiotaki, Simon Walker-Samuel, Bernard Siow, S. Peter Johnson, Vineeth Rajkumar, R. Barbara Pedley, Mark F. Lythgoe and Daniel C. AlexanderCancer Res April 1 2014 74 (7) 1902-1912; DOI:10.1158/0008-5472.CAN-13-2511
This article highlights the superior qualities of a novel noninvasive imaging method to monitor tumor development and therapeutic response in preclinical models.
- Integrated Systems and TechnologiesThomas G. Weber, Franz Osl, Anja Renner, Thomas Pöschinger, Stefanie Galbán, Alnawaz Rehemtulla and Werner ScheuerCancer Res April 1 2014 74 (7) 1913-1923; DOI:10.1158/0008-5472.CAN-13-3001
This preclinical study reports a method to quantify antibody accumulation and pharmacodynamics in brain tumors, where delivery after systemic administration is often difficult to assess, offering a holistic in vivo approach to assess CNS-targeting drugs.
Microenvironment and Immunology
- Microenvironment and ImmunologyJ. Louise Lines, Eirini Pantazi, Justin Mak, Lorenzo F. Sempere, Li Wang, Samuel O'Connell, Sabrina Ceeraz, Arief A. Suriawinata, Shaofeng Yan, Marc S. Ernstoff and Randolph NoelleCancer Res April 1 2014 74 (7) 1924-1932; DOI:10.1158/0008-5472.CAN-13-1504
Therapeutic inactivation of CTLA-4–related molecules like VISTA may have enormous potential for generalized immunotherapy of cancer.
- Microenvironment and ImmunologyIsabelle Le Mercier, Wenna Chen, Janet L. Lines, Maria Day, Jiannan Li, Petra Sergent, Randolph J. Noelle and Li WangCancer Res April 1 2014 74 (7) 1933-1944; DOI:10.1158/0008-5472.CAN-13-1506
This study offers a preclinical proof-of-concept to evaluate the efficacy and mechanisms of action of a VISTA-targeting antibody in multiple tumor models.
- Microenvironment and ImmunologyAndressa Ardiani, Sofia R. Gameiro, Claudia Palena, Duane H. Hamilton, Anna Kwilas, Thomas H. King, Jeffrey Schlom and James W. HodgeCancer Res April 1 2014 74 (7) 1945-1957; DOI:10.1158/0008-5472.CAN-13-2045
This study offers a preclinical proof-of-concept for an antimetastasis vaccine targeting Twist, a transcription factor that promotes metastasis and drug resistance in many tumor types.
- Microenvironment and ImmunologyIrene Romero, Cristina Garrido, Ignacio Algarra, Antonia Collado, Federico Garrido and Angel M. Garcia-LoraCancer Res April 1 2014 74 (7) 1958-1968; DOI:10.1158/0008-5472.CAN-13-2084
This study describes a preclinical model for dormant metastases controlled by the immune system, an understanding of which may lead to new insights into how to extend survival by blocking relapses of metastatic cancer.
- Microenvironment and ImmunologyShoubao Ma, Qiao Cheng, Yifeng Cai, Huanle Gong, Yan Wu, Xiao Yu, Liyun Shi, Depei Wu, Chen Dong and Haiyan LiuCancer Res April 1 2014 74 (7) 1969-1982; DOI:10.1158/0008-5472.CAN-13-2534
These findings offer new insights into how the proinflammatory cytokine IL-17A influences tumor immunity, with potential implications for the development of tumor immunotherapy.
Molecular and Cellular Pathobiology
- Molecular and Cellular PathobiologyMélanie J. Domingues, Florian Rambow, Bastien Job, Laura Papon, Wanguo Liu, Lionel Larue and Jacky BonaventureCancer Res April 1 2014 74 (7) 1983-1995; DOI:10.1158/0008-5472.CAN-13-0920
ICAT inhibition reduces the mesenchymal amoeboid transition involved in invasive cancer cell motility, limiting metastasis formation.
- Molecular and Cellular PathobiologyAlexey Tyryshkin, Abhisek Bhattacharya and N. Tony EissaCancer Res April 1 2014 74 (7) 1996-2005; DOI:10.1158/0008-5472.CAN-13-1256
This study provides a mechanistic rationale to immediately reposition the use of Src inhibitors currently in clinical trials for the treatment of malignancies associated with mutation of the tumor suppressor gene TSC2.
- Molecular and Cellular PathobiologyYingMeei Tan, Dahui Sun, Weijian Jiang, Kathleen Klotz-Noack, Ajay A. Vashisht, James Wohlschlegel, Martin Widschwendter and Charles SpruckCancer Res April 1 2014 74 (7) 2006-2014; DOI:10.1158/0008-5472.CAN-13-1263
As a candidate therapeutic target, overexpressed cyclin E1 is a driving force of hormone-independent growth, genetic instability, and progression of “triple-negative” breast cancers and other aggressive cancers.
- Molecular and Cellular PathobiologyStéphanie Bianco, Mylène Brunelle, Maïka Jangal, Luca Magnani and Nicolas GévryCancer Res April 1 2014 74 (7) 2015-2025; DOI:10.1158/0008-5472.CAN-13-2351
This study shows how the nuclear receptor LRH-1 modulates the sensitivity of breast cancer cells to antiestrogen therapy, suggesting new insights into how resistance may emerge to limit treatment effectiveness.
- Molecular and Cellular PathobiologyXing Wang, Zhiheng He, Tian Xia, Xiaofan Li, Deguang Liang, Xianzhi Lin, Hao Wen and Ke LanCancer Res April 1 2014 74 (7) 2026-2037; DOI:10.1158/0008-5472.CAN-13-1467
These findings identify a therapeutic target for treatment of Kaposi sarcoma, a cancer best known for its association with AIDS patients at highest risk of this herpesvirus-driven disease.
- Molecular and Cellular PathobiologyHidetaka Ohnuki, Kan Jiang, Dunrui Wang, Ombretta Salvucci, Hyeongil Kwak, David Sánchez-Martín, Dragan Maric and Giovanna TosatoCancer Res April 1 2014 74 (7) 2038-2049; DOI:10.1158/0008-5472.CAN-13-3118
This study describes a myeloid cell–carcinoma signaling network that links the tumor microenvironment in new ways with tumor growth, highlighting opportunities to target tumors where this network is active.
Therapeutics, Targets, and Chemical Biology
- Therapeutics, Targets, and Chemical BiologyLiya Ding, Shuai Chen, Ping Liu, Yunqian Pan, Jian Zhong, Kevin M. Regan, Liguo Wang, Chunrong Yu, Anthony Rizzardi, Liang Cheng, Jun Zhang, Stephen C. Schmechel, John C. Cheville, Jan Van Deursen, Donald J. Tindall and Haojie HuangCancer Res April 1 2014 74 (7) 2050-2061; DOI:10.1158/0008-5472.CAN-13-1659
These results suggest new insights into prostate cancer etiology, establishing a central role for histone modification and providing a rationale for clinical evaluation of epigenetic-targeted therapy in prostate cancer patients.
- Therapeutics, Targets, and Chemical Biology | AuthorChoiceNagaraj S. Nagathihalli, Yugandhar Beesetty, Wooin Lee, M. Kay Washington, Xi Chen, A. Craig Lockhart and Nipun B. MerchantCancer Res April 1 2014 74 (7) 2062-2072; DOI:10.1158/0008-5472.CAN-13-2329
These findings define an EGF-related signaling pathway that mediates the oncogenic effects of secondary bile acids in gastrointestinal cancers, the targeting of which may enhance therapeutic responses.
- Therapeutics, Targets, and Chemical BiologyRong Zhong, Matt Pytynia, Charles Pelizzari and Michael SpiottoCancer Res April 1 2014 74 (7) 2073-2081; DOI:10.1158/0008-5472.CAN-13-2993
More rapid visualization of HPV-positive oral tumor growth will assist the development of chemotherapeutic and radiotherapeutic strategies to stem this rapidly growing disease.
Tumor and Stem Cell Biology
- Tumor and Stem Cell BiologyZehua Zhu, Kristina Todorova, Kevin K. Lee, Jun Wang, Eunjeong Kwon, Ivan Kehayov, Hyung-Gu Kim, Vihren Kolev, G. Paolo Dotto, Sam W. Lee and Anna MandinovaCancer Res April 1 2014 74 (7) 2082-2093; DOI:10.1158/0008-5472.CAN-12-0452
These findings describe an important regulatory feedback on a key tumor suppressor pathway that may have a pivotal role in epithelial tumors.
- Tumor and Stem Cell BiologyDavid C. de Leeuw, Fedor Denkers, Marjolein C. Olthof, Arjo P. Rutten, Walter Pouwels, Gerrit Jan Schuurhuis, Gert J. Ossenkoppele and Linda SmitCancer Res April 1 2014 74 (7) 2094-2105; DOI:10.1158/0008-5472.CAN-13-1733
These findings define miR-126 as a therapeutic focus to specifically eradicate stem-like cells in acute myeloid leukemias that tend to relapse in patients despite early positive responses to chemotherapy.
- Tumor and Stem Cell BiologyAnna Pastò, Valentina Serafin, Giorgia Pilotto, Claudia Lago, Chiara Bellio, Livio Trusolino, Andrea Bertotti, Timothy Hoey, Michelina Plateroti, Giovanni Esposito, Marica Pinazza, Marco Agostini, Donato Nitti, Alberto Amadori and Stefano IndraccoloCancer Res April 1 2014 74 (7) 2106-2118; DOI:10.1158/0008-5472.CAN-13-2022
These findings point to a specific inhibition of NOTCH2/3, rather than NOTCH1, as a strategy for attacking cancer stem-like cells in metastatic colon cancer.
- Tumor and Stem Cell BiologyTao Deng, Jeff C. Liu, Philip E.D. Chung, David Uehling, Ahmed Aman, Babu Joseph, Troy Ketela, Zhe Jiang, Nathan F. Schachter, Robert Rottapel, Sean E. Egan, Rima Al-awar, Jason Moffat and Eldad ZacksenhausCancer Res April 1 2014 74 (7) 2119-2130; DOI:10.1158/0008-5472.CAN-13-2138
These results identify a novel target to improve treatment of HER2-positive breast cancer through leveraging existing anti-HER2 therapy.
Correction
- CorrectionCancer Res April 1 2014 74 (7) 2131-2131; DOI:10.1158/0008-5472.CAN-14-0557
April 2014
Volume 74, Issue 7
Volume 74, Issue 7
Issue Highlights
Jump to
Advertisement
